Signals
Metabolic syndrome may leave a signature in mitochondrial DNA. The biomarker race should not outrun the evidence
A small pilot study has linked mitochondrial DNA variation in blood monocytes with vascular stenosis, glucose, insulin, cholesterol and inflammatory activity in people with obesity and metabolic syndrome. The findings point toward a more personalised understanding of cardiometabolic disease, but they are nowhere near ready to become a diagnostic test.
AI Pathology Starts Moving Toward Treatment Selection
Hepatitis B Functional Cure Moves Closer, But Access Still Starts With Diagnosis
A Urine Test for Alzheimer’s Would Change the Access Conversation
AI Multiomics Moves Into the Trial Stratification Layer
IAPM Launches Oncology Pillar at ASCO: Closing the Gap Between Cancer Breakthroughs and Patient Access
WHA 2026: WHO resolution moves precision medicine onto the global health policy agenda
ASCO 2026: Pancreatic cancer gets its precision medicine moment
ASCO 2026: GI cancers are finally moving out of oncology’s blind spot
ASCO 2026: AI is entering cancer care before the rules are ready
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.